BRAINTREE, Mass., May 6 /PRNewswire-FirstCall/ -- Haemonetics Corporation announced today that Brad Nutter, Chairman and CEO, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934.
Rule 10b5-1 plans allow executives to adopt a pre-arranged stock trading plan to buy or sell a specified number of shares of the company's stock. Under the plan, Mr. Nutter will exercise only the new-hire stock options granted to him in 2003 when he was hired by Haemonetics as President and CEO. In 2007, Mr. Nutter was promoted to the position of Chairman of the Board of Directors and CEO. Mr. Nutter is entering into the plan for portfolio diversification purposes.
Mr. Nutter remains in compliance with Haemonetics' executive stock ownership plan.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to
providing innovative blood management solutions for our customers.
Together, our devices and consumables, information technology platforms,
and consulting services deliver a suite of business solutions to help our
customers improve clinical outcomes and reduce the cost of healthcare for
blood collectors, hospitals, and patients around the world. Our
technologies address important medical markets: blood and plasma component
collection, the surgical suite, and hospital transfusion services. To learn
more about Haemonetics, visit our web site at http://www.haemonetics.com.
Tel. (781) 356-9517
Alternate Tel. (617) 320-2401
|SOURCE Haemonetics Corporation|
Copyright©2008 PR Newswire.
All rights reserved